GALAPAGOS NV (GLPG) Stock
7 of the hedge funds AlphaScala tracks reported GLPG in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Greenlight Capital's at $14.47M.
Which hedge funds own GLPG?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Greenlight Capital David Einhorn | 483K | $14.47M | n/a |
| Renaissance Technologies Jim Simons (founder) | 408K | $12.23M | +29% |
| Point72 Steve Cohen | 270K | $8.09M | -19% |
| D.E. Shaw David Shaw | 198K | $5.93M | -8% |
| Millennium Management Israel Englander | 181K | $5.43M | +68% |
| Citadel Ken Griffin | 88K | $2.65M | -29% |
| Marshall Wace | 32K | $971.3K | NEW |
13F holdings as of Jun 30, 2026
Explore all tracked funds →GLPG price chart
Powered by TradingViewWhat does GALAPAGOS NV do?
Galapagos NV American Depositary Receipt represents shares in Galapagos NV, a fully integrated biotechnology company headquartered in Mechelen, Belgium, and founded in 1999. The company focuses on transforming patient outcomes through life-changing science and innovation in immunology and oncology. It develops best-in-class therapies using multiple drug modalities, including small molecules, biologicals, and advanced cell therapies such as CAR-T products manufactured via a decentralized, point-of-care platform for rapid vein-to-vein delivery. Key therapeutic areas encompass immunology indications like rheumatoid arthritis, ulcerative colitis, axial spondyloarthritis, dermatomyositis, and systemic lupus erythematosus, alongside oncology programs targeting non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, and multiple myeloma. Galapagos synergizes internal expertise with external partnerships to accelerate discovery, development, and delivery of innovative medicines addressing high unmet medical needs. With operations spanning Europe and the United States, it maintains a deep pipeline and collaborates with leading organizations to pioneer next-generation treatments for serious diseases.